Xyzal: Advanced 24-Hour Relief from Allergic Rhinitis and Chronic Hives
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.52 | $50.48 (0%) | 🛒 Add to cart |
| 30 | $2.22 | $75.72 $66.64 (12%) | 🛒 Add to cart |
| 60 | $1.92 | $151.44 $115.10 (24%) | 🛒 Add to cart |
| 90 | $1.62 | $227.17 $145.39 (36%) | 🛒 Add to cart |
| 120 | $1.31 | $302.89 $157.50 (48%) | 🛒 Add to cart |
| 180 | $1.01 | $454.33 $181.73 (60%) | 🛒 Add to cart |
| 270 | $0.81 | $681.50 $218.08 (68%) | 🛒 Add to cart |
| 360 | $0.71
Best per pill | $908.66 $254.43 (72%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.79 | $47.45 (0%) | 🛒 Add to cart |
| 90 | $0.64 | $71.18 $57.55 (19%) | 🛒 Add to cart |
| 120 | $0.54 | $94.90 $64.62 (32%) | 🛒 Add to cart |
| 180 | $0.48 | $142.36 $85.82 (40%) | 🛒 Add to cart |
| 270 | $0.40 | $213.54 $109.04 (49%) | 🛒 Add to cart |
| 360 | $0.35
Best per pill | $284.71 $127.21 (55%) | 🛒 Add to cart |
Synonyms | |||
Xyzal (levocetirizine dihydrochloride) is a potent, second-generation antihistamine specifically formulated to provide long-lasting relief from allergy symptoms and chronic idiopathic urticaria. As the active enantiomer of cetirizine, it delivers targeted histamine H1-receptor blockade with minimal sedative effects, making it a preferred choice for both patients and clinicians. This prescription medication offers superior symptom control with a once-daily dosing regimen, supporting improved quality of life for allergy sufferers. Its well-established efficacy and safety profile have made it a mainstay in allergic condition management protocols worldwide.
Features
- Active ingredient: Levocetirizine dihydrochloride 5 mg per tablet
- Pharmacological class: Second-generation antihistamine (H1-receptor antagonist)
- Administration: Oral tablet formulation
- Duration of action: 24-hour sustained relief
- Prescription status: Rx-only medication
- Packaging: Blister packs containing 5, 10, or 15 tablets
- Bioavailability: Rapid absorption with peak plasma concentrations within 0.9 hours
- Metabolism: Minimal hepatic metabolism (approximately 14% of dose)
- Excretion: Primarily renal elimination (85.4% of dose unchanged in urine)
Benefits
- Provides comprehensive 24-hour relief from allergic rhinitis symptoms including sneezing, rhinorrhea, nasal congestion, and ocular symptoms
- Effectively manages chronic idiopathic urticaria through potent histamine receptor blockade
- Demonstrates rapid onset of action with symptom improvement within one hour of administration
- Offers non-sedating therapy for most patients due to minimal blood-brain barrier penetration
- Supports improved sleep quality and daytime functioning by controlling nighttime allergy symptoms
- Features simple once-daily dosing that enhances medication adherence and treatment consistency
Common use
Xyzal is primarily indicated for the relief of symptoms associated with perennial and seasonal allergic rhinitis in adults and children 6 years of age and older. These symptoms include nasal congestion, sneezing, rhinorrhea, pruritus, and ocular manifestations such as tearing and redness. Additionally, it is approved for the treatment of chronic idiopathic urticaria, providing relief from wheals and pruritus associated with this condition. Clinical studies have demonstrated its efficacy in improving quality of life measures related to allergic conditions, particularly in reducing symptom interference with daily activities and sleep patterns.
Dosage and direction
The recommended dosage for adults and children 12 years and older is 5 mg (one tablet) once daily in the evening. For children 6 to 11 years of age, the recommended dose is 2.5 mg (half tablet) once daily in the evening. Administration should occur at approximately the same time each day to maintain consistent plasma concentrations. Tablets should be swallowed whole with a small amount of water and may be taken with or without food, though food may slightly delay absorption. Dosage adjustment is necessary in patients with renal impairment: for creatinine clearance 50-80 mL/min, no adjustment needed; 30-50 mL/min, 2.5 mg once daily; 10-30 mL/min, 2.5 mg every other day; and <10 mL/min or hemodialysis patients, use is not recommended.
Precautions
Patients should be advised that Xyzal may cause somnolence in some individuals, although the incidence is comparable to placebo at therapeutic doses. Activities requiring mental alertness, such as operating machinery or driving, should be undertaken with caution until the patient’s response to the medication is established. Concurrent use with alcohol or other central nervous system depressants may potentiate sedative effects. Renal function should be assessed in elderly patients and those with suspected renal impairment before initiation. Patients with predisposing factors for urinary retention (such as prostatic hyperplasia) should use with caution due to anticholinergic effects. Periodic evaluation of treatment efficacy and side effects is recommended during long-term therapy.
Contraindications
Xyzal is contraindicated in patients with known hypersensitivity to levocetirizine, cetirizine, or any component of the formulation. It is also contraindicated in patients with end-stage renal disease (creatinine clearance <10 mL/min) and those undergoing hemodialysis. Use is contraindicated in children under 6 years of age due to insufficient safety and efficacy data in this population. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medication due to the lactose content in the tablet formulation.
Possible side effects
The most commonly reported adverse reactions (≥2% and greater than placebo) include somnolence (6% vs 2% placebo), nasopharyngitis (4% vs 3%), pyrexia (3% vs 1%), fatigue (3% vs 1%), and dry mouth (3% vs 1%). Less frequent side effects include headache, pharyngitis, abdominal pain, and cough. In pediatric patients 6-12 years, somnolence occurred in 3% compared to 1% with placebo. Serious but rare adverse effects include hypersensitivity reactions, seizures, and hepatitis. Most adverse reactions are mild to moderate in severity and often diminish with continued therapy. Patients should report any persistent or bothersome side effects to their healthcare provider.
Drug interaction
Formal drug interaction studies have shown no clinically significant interactions with pseudoephedrine, ketoconazole, azithromycin, or theophylline. However, caution is advised when co-administering with CNS depressants including alcohol, barbiturates, benzodiazepines, and opioid analgesics due to potential additive sedative effects. Theoretically, medications that inhibit renal tubular secretion (such as probenecid) may decrease the clearance of levocetirizine, though clinical significance remains uncertain. No interactions have been observed with warfarin at therapeutic doses. Healthcare providers should review all concomitant medications before prescribing Xyzal.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. The extended half-life of levocetirizine (approximately 8-9 hours) provides some buffer against temporary lapses in dosing, but consistent daily administration is recommended for optimal symptom control. Setting daily reminders or taking the medication as part of an evening routine can help prevent missed doses.
Overdose
In case of overdose, symptoms may include somnolence, agitation, restlessness, and tachycardia in adults, while children may primarily exhibit agitation and restlessness followed by drowsiness. There is no specific antidote for levocetirizine overdose. Management should include gastric lavage or activated charcoal if presentation occurs within 2 hours of ingestion. Supportive and symptomatic treatment is recommended, with particular attention to respiratory and cardiovascular status. Hemodialysis removes approximately 10% of the administered dose and may be considered in severe cases. Patients suspected of overdose should seek immediate medical attention or contact a poison control center.
Storage
Store Xyzal tablets at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep the medication in its original blister packaging to protect from moisture and light. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Properly discard any expired or unused medication according to local regulations, typically through medication take-back programs or by mixing with undesirable substances in sealed containers before disposal in household trash. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Xyzal is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the same benefits or side effects. Patients should consult their healthcare provider for proper diagnosis and treatment recommendations based on their specific medical condition, overall health status, and complete medical history. The manufacturer and distributors are not liable for any adverse outcomes resulting from the use or misuse of this information.
Reviews
Clinical studies demonstrate that 78% of patients with seasonal allergic rhinitis experienced significant symptom improvement with Xyzal compared to 59% with placebo. In chronic idiopathic urticaria trials, 63% of patients showed marked reduction in wheal numbers and pruritus intensity. Patient satisfaction surveys indicate high rates of continued use due to effective symptom control and favorable side effect profile. Healthcare providers frequently report positive experiences with Xyzal, particularly noting its efficacy in patients who have responded inadequately to other antihistamines. Real-world evidence supports the clinical trial data, confirming its position as a valuable therapeutic option in allergy management.